Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2109 - Independent prognostic impact of lympho-vascular invasion in cutaneous melanoma patients with sentinel lymph node biopsy


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Melanoma




Annals of Oncology (2017) 28 (suppl_5): v428-v448. 10.1093/annonc/mdx377


R. Luca, M. Rizzo, P. Mando, C. Perez de La Puente, A. Blanco, S. Rivero, G. Lutter, F. Cappuccio, M. Amat, J. Kaplan, R. Chacon, M. Chacon

Author affiliations

  • Medical Oncology, Instituto Alexander Fleming, 1426 - CABA/AR


Abstract 2109


Incidence of cutaneous melanoma (CM) is increasing worldwide. The primary treatment of CM is surgery. Prognosis is determined by characteristics of the lesion such as depth of invasion, ulceration and sentinel lymph node (SLN) status. The aim of this study was to analyze the prognostic impact of lympho-vascular invasion (LVI) in CM patients (pts) undergoing SLN biopsy since LVI has not been established as a clear prognostic factor in the current AJCC 8th ed. cancer staging system.


Retrospective, descriptive and observational analytical study. We used the institutional database of pts with diagnosis of CM, submitted to SLN biopsy between November 1994 and August 2016. The association between pathological characteristics and SLN were analyzed using Chi2 and logistic regression model. Kaplan Meier and Log rank were used for disease free survival (DFS) analysis.


385 pts with a diagnosis of CM were analyzed. Median follow-up 45.2 months (IQR: 15.66-91.77). Median age: 52 years (IQR 42-65). SLN+: 47/384 (12.2%). Evaluated prognostic factors: Breslow (Br) 1.5 mm md (IQR 1-2.67), ulceration + 94/385 (24.4%), LVI + 32/144 (22.2%). Relapse 86/367 (23.4%). In the univariate analysis we found association between relapse and the following factors: LVI + (OR: 2.97, p = 0.0125), SLN + (OR: 3.97, p 


In our retrospective series, after a long period of follow-up, the presence of LVI as an independent factor was associated with relapse and DFS. Within CM pts the best candidate for adjuvant therapy is yet to be defined, LVI + as a prognostic factor should be validated in prospective trials in this scenario.

Clinical trial identification

Legal entity responsible for the study

Instituto Alexander Fleming


Instituto Alexander Fleming


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.